Profound Medical Corp. (PROF)
| Market Cap | 182.50M |
| Revenue (ttm) | 10.68M |
| Net Income (ttm) | -27.82M |
| Shares Out | 30.04M |
| EPS (ttm) | -1.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 406,656 |
| Open | 6.17 |
| Previous Close | 6.19 |
| Day's Range | 4.75 - 6.28 |
| 52-Week Range | 4.75 - 11.42 |
| Beta | 0.77 |
| Analysts | Strong Buy |
| Price Target | 12.00 (+98.35%) |
| Earnings Date | Mar 6, 2025 |
About PROF
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate... [Read more]
Financial Performance
In 2024, Profound Medical's revenue was $10.68 million, an increase of 48.35% compared to the previous year's $7.20 million. Losses were -$27.82 million, -1.79% less than in 2023.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for PROF stock is "Strong Buy" and the 12-month stock price forecast is $12.0.
News
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Profound Medical Corp. (PROF) and Encourages Stockholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (...
Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Investors to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (...
Wolf Haldenstein Adler Freeman & Herz LLP is investigating Profound Medical Corp. for potential violations of securities laws
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Investors to Reach Out
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Stockholders to Reach Out
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Stockholders to Connect
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (...
PROF Investors Have Opportunity to Join Profound Medical Corp. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--PROF Investors Have Opportunity to Join Profound Medical Corp. Fraud Investigation with the Schall Law Firm.
Profound Medical Corporation (PROF) Q4 2024 Earnings Conference Call Transcript
Profound Medical Corporation (NASDAQ:PROF) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Stephen Kilmer – IR Rashed Dewan - CFO Mathieu Burtnyk - COO Tom Tamberrino -...
Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow
TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...
Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues
– Fourth quarter revenue growth estimated at 105% to 110% year-over-year – – Company to start reporting in accordance with U.S. GAAP and filing with the SEC on U.S. domestic forms – – Profound reminds...
Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference
TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...
Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares
TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced the closing of its previously announced underwritten public off...
Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR
Profound Medical Announces Proposed Public Offering of Common Shares
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR
Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy
– Combines Profound's TULSA-PRO ® and Siemens Healthineers' Magnetom Free.Max – – Supports the Modern Treatment Pathway that allows for more accurate and precise diagnosis, treatment, and follow-up – ...
Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant'
TULSA procedure's unrivaled flexibility, real-world efficacy and ongoing CAPTAIN post-market study to be featured in the scientific programs at the upcoming RSNA and SUO meetings TULSA procedure's unr...
Profound Medical Corporation (PROF) Q3 2024 Earnings Call Transcript
Profound Medical Corporation (NASDAQ:PROF) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Stephen Kilmer - IR Arun Menawat - CEO Rashed Dewan - CFO Mathieu Burtnyk ...
Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025
– TULSA to stand above all other covered prostate disease treatment modalities at Urology Level 7 reimbursement – – First-time CPT® code reimbursement for TULSA to be effective January 1, 2025 – TORON...
Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow
TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...
Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer
– Mr. Tamberrino and Profound's CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 –
Profound Medical to Participate in Lake Street's Best Ideas Growth Conference
TORONTO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizabl...
Profound Medical Corporation (PROF) Q2 2024 Earnings Call Transcript
Profound Medical Corporation (NASDAQ:PROF) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Stephen Kilmer - IR Arun Menawat - CEO Rashed Dewan - CFO Mathieu Burtnyk - ...
Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow
TORONTO, July 18, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...
Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases
TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...
Profound Medical Annual General Meeting of Shareholders Voting Results
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General Meeting of Sha...